BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tetrodotoxin: Phase III ongoing

Wex said that a DMC informed the company that the ongoing double-blind, placebo-controlled, Canadian Phase III TEC-006 trial of tetrodotoxin is unlikely to show a clinically meaningful treatment-effect difference on the primary composite endpoint combining pain outcome and quality of...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >